(TSX:FRX),(NASDAQ:FENC), RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered public offering. In addition, Fennec intends to grant the underwriters a 30-day option to purchase […]
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares GlobeNewswire November 13, 2025 RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered public offering. In addition,
(NASDAQ:FLNT), • Q3 2025 revenue of $47.0 million; YTD 2025 revenue of $146.9 million • Q3 2025 Commerce Media Solutions revenue grew 81% to $18.8 million, representing 40% of consolidated revenue from $10.4 million or 16% of consolidated revenue in Q3 2024 • Commerce Media Solutions annual revenue run rate now exceeds $85 million, with
(NASDAQ:NDAQ), NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) will be presenting at the following conferences with webcasts available at Nasdaq's Investor Relations website: ir.nasdaq.com/events.cfm. Who: Sarah Youngwood, Executive Vice President and CFO, Nasdaq What: J.P. Morgan 2025 Ultimate Services Investor Conference When: Wednesday, November 18, 20252:00 PM ET Who: Sarah Youngwood,
(NASDAQ:HYPD), Management Initiates Q4'25 Adjusted Revenue(3) Guidance of 31% to 43% Q-o-Q Growth Over 13 Million HYPE Tokens Staked to Hyperion's Validator as of October 31, 2025 Ramping Business Lines Expected to Achieve Positive Operating Cash Flows in 2026 LAGUNA HILLS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi”
(TSX:PRN),(NASDAQ:PROF), TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all amounts in
(NASDAQ:SHIM), IRVINE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Shimmick Corp. (NASDAQ: SHIM), a leading infrastructure solutions provider in water, electrical and other critical infrastructure construction services, today announced financial results for the third quarter ended October 3, 2025. Third Quarter 2025 and Recent Highlights Reported revenue of $142 million, with $107 million coming from
(NASDAQ:HDSN), WOODCLIFF LAKE, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) (the “Company”) today announced that its Board of Directors has appointed Kenneth Gaglione as Chairman of the Board, President and Chief Executive Officer, effective November 24, 2025. Mr. Gaglione brings a wealth of experience in the refrigerants and specialty chemicals
(NASDAQ:AARD), Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) New preclinical data presented at ObesityWeek 2025 demonstrates the potential of ARD-201 in enhanced
TSX/NYSE/PSE: MFC SEHK: 945 Phil Witherington, President and Chief Executive Officer, Manulife, will participate in a fireside chat with TD Securities Analyst, Mario Mendonca on Wednesday, November 19, 2025, to discuss the company's recent business performance and refreshed enterprise strategy. The event is scheduled to begin at 9:00 a.m. ET. https://mma.prnewswire.com/media/2822826/Manulife_Financial_Corporation_Manulife_President_and_Chief_Exec.jpg A live webcast and